Clarithromycin Accord 250 mg Norvège - norvégien - Statens legemiddelverk

clarithromycin accord 250 mg

accord healthcare b.v. - klaritromycin - tablett, filmdrasjert - 250 mg

Hepcludex Union européenne - norvégien - EMA (European Medicines Agency)

hepcludex

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirale midler til systemisk bruk - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Alitretinoin Orifarm 10 mg Norvège - norvégien - Statens legemiddelverk

alitretinoin orifarm 10 mg

orifarm generics a/s - alitretinoin - kapsel, myk - 10 mg

Alitretinoin Orifarm 30 mg Norvège - norvégien - Statens legemiddelverk

alitretinoin orifarm 30 mg

orifarm generics a/s - alitretinoin - kapsel, myk - 30 mg

Cabazitaxel Accord Union européenne - norvégien - EMA (European Medicines Agency)

cabazitaxel accord

accord healthcare s.l.u. - cabazitaxel - prostatic neoplasmer, kastrering-resistant - antineoplastiske midler - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Cabazitaxel STADA 20 mg/ ml Norvège - norvégien - Statens legemiddelverk

cabazitaxel stada 20 mg/ ml

stada arzneimittel ag - kabazitaksel - konsentrat til infusjonsvæske, oppløsning - 20 mg/ ml

Qinlock Union européenne - norvégien - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Pyrukynd Union européenne - norvégien - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Tibsovo Union européenne - norvégien - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Lapatinib Newbury 250 mg Norvège - norvégien - Statens legemiddelverk

lapatinib newbury 250 mg

newbury pharmaceuticals ab - lapatinib ditosylatmonohydrat - tablett, filmdrasjert - 250 mg